PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 82.32

Change

+0.69 (+0.85)%

Market Cap

N/A

Volume

0.46M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.08 (+1.77%)

USD 79.77B
TAK Takeda Pharmaceutical Co Ltd A..

+0.02 (+0.15%)

USD 45.03B
HLN Haleon plc

-0.05 (-0.54%)

USD 43.99B
RDY Dr. Reddy’s Laboratories Ltd..

-0.21 (-1.42%)

USD 12.67B
CTLT Catalent Inc

-0.10 (-0.17%)

USD 10.78B
ELAN Elanco Animal Health

+0.07 (+0.50%)

USD 6.96B
BHC Bausch Health Companies Inc

-0.35 (-3.83%)

USD 3.37B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.22 (-2.38%)

USD 2.80B
CPHI China Pharma Holdings Inc

N/A

USD 3.43M
YCBD cbdMD Inc

-0.05 (-9.04%)

USD 1.73M

ETFs Containing PBH

NDIA Global X Funds 3.47 % 0.00 %

-0.34 (-1.11%)

USD 0.03B
XST:CA iShares S&P/TSX Capped Co.. 3.17 % 0.61 %

-0.55 (-1.11%)

CAD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.47% 67% D+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.47% 67% D+ 87% B+
Trailing 12 Months  
Capital Gain 40.55% 60% D- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.55% 60% D- 83% B
Trailing 5 Years  
Capital Gain 118.70% 93% A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 118.70% 93% A 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 16.83% 87% B+ 78% C+
Dividend Return 16.83% 87% B+ 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.03% 73% C 52% F
Risk Adjusted Return 80.01% 100% F 89% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector